{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:59:54Z","timestamp":1789610394655,"version":"build-2803163510"},"update-to":[{"DOI":"10.1002\/14651858.cd006201.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2013,6,28]],"date-time":"2013-06-28T00:00:00Z","timestamp":1372377600000}}],"reference-count":59,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006201.pub3","type":"journal-article","created":{"date-parts":[[2013,6,28]],"date-time":"2013-06-28T10:59:10Z","timestamp":1372417150000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Chemotherapy for second-stage Human African trypanosomiasis"],"prefix":"10.1002","volume":"2013","author":[{"given":"Vittoria","family":"Lutje","sequence":"first","affiliation":[{"name":"Liverpool School of Tropical Medicine; Department of Clinical Sciences; Pembroke Place Liverpool UK L3 5QA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Seixas","sequence":"additional","affiliation":[{"name":"Instituto de Higiene e Medicina Tropical; Rua da Junqueira 96 PT 1349-008 Lisbon Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Kennedy","sequence":"additional","affiliation":[{"name":"St James University Hospital; Burmantofts Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,6,28]]},"reference":[{"key":"10.1002\/14651858.CD006201.pub3-BIB0001|cit1","doi-asserted-by":"crossref","unstructured":"Bisser S N'Siesi FX Lejon V Preux PM Van Nieuwenhove S Miaka Mia Bilenge C Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness Journal of Infectious Diseases 2007 322 9","DOI":"10.1086\/510534"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"Burri C Nkunku S Merolle A Smith T Blum J Brun R Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial Lancet 2000 1419 25","DOI":"10.1016\/S0140-6736(00)02141-3"},{"issue":"9436","key":"10.1002\/14651858.CD006201.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(04)16940-7","article-title":"Efficacy of 10-day melarsoprol schedule 2 years after treatment for late-stage gambiense sleeping sickness","volume":"364","author":"Schmid","year":"2004","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD006201.pub3-BIB0004|cit4","first-page":"278","volume":"61","author":"Legros","year":"2001","journal-title":"Medecine Tropicale"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0005|cit5","doi-asserted-by":"crossref","unstructured":"Lejon V Legros D Savignoni A Etchegorry MG Mbulamberi D Buscher P Neuro-inflammatory risk factors for treatment failure in \"early second stage\" sleeping sickness patients treated with pentamidine Journal of Neuroimmunology 2003 132 8","DOI":"10.1016\/j.jneuroim.2003.08.033"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0006|cit6","doi-asserted-by":"crossref","unstructured":"Na-Bangchang K Doua F Konsil J Hanpitakpong W Kamanikom B Kuzoe F The pharmacokinetics of eflornithine (alpha-difluoromethylornithine) in patients with late-stage T.b. gambiense sleeping sickness European Journal of Clinical Pharmacology 2004 269 78","DOI":"10.1007\/s00228-004-0759-7"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0007|cit7","doi-asserted-by":"crossref","unstructured":"Pepin J Milord F Guern C Mpia B Ethier L Mansinsa D Trial of prednisolone for prevention of melarsoprol-induced encephalopathy in gambiense sleeping sickness Lancet 1989 1246 50","DOI":"10.1016\/S0140-6736(89)92340-4"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0008|cit8","unstructured":"Pepin J Khonde N Maiso F Doua F Jaffar S Ngampo S Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial Bulletin of the World Health Organization 2000 1284 95"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0009|cit9","doi-asserted-by":"crossref","unstructured":"Pepin J Mpia B Randomized controlled trial of three regimens of melarsoprol in the treatment of Trypanosoma brucei gambiense trypanosomiasis Transactions of the Royal Society of Tropical Medicine and Hygiene 2006 437 41","DOI":"10.1016\/j.trstmh.2005.03.017"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0010|cit10","doi-asserted-by":"crossref","unstructured":"Priotto G Fogg C Balasegaram M Erphas O Louga A Checchi F Three Drug Combinations for Late-Stage Trypanosoma brucei gambiense Sleeping Sickness: A Randomized Clinical Trial in Uganda PLoS Clinical Trials 2006 e39","DOI":"10.1371\/journal.pctr.0010039"},{"issue":"9683","key":"10.1002\/14651858.CD006201.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(09)61117-X","article-title":"Nifurtimox-eflornithine combination therapy for second-stage African Trypanosoma brucei gambiense trypanosomiasis: a multicentre, randomised, phase III, non-inferiority trial","volume":"374","author":"Priotto","year":"2009","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD006201.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1086\/522982","article-title":"Nifurtimox-eflornithine combination therapy for second-stage Trypanosoma brucei gambiense sleeping sickness: a randomized clinical trial in Congo","volume":"45","author":"Priotto","year":"2007","journal-title":"Clinical infectious diseases"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0013|cit13","doi-asserted-by":"crossref","unstructured":"APTED FI Four years' experience of melarsen oxide\/BAL in the treatment of late-stage Rhodesian sleeping sickness Transactions of the Royal Society of Tropical Medicine and Hygiene 1957 75 86","DOI":"10.1016\/0035-9203(57)90010-X"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0014|cit14","doi-asserted-by":"crossref","unstructured":"Balasegaram M Harris S Checchi F Ghorashian S Hamel C Karunakara U Melarsoprol versus eflornithine for treating late-stage Gambian trypanosomiasis in the Republic of the Congo Bulletin of the World Health Organization 2006 783 91","DOI":"10.2471\/BLT.06.031955"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0015|cit15","unstructured":"Burri C Blum J Brun R Alternative application of melarsoprol for treatment of T. B. gambiense sleeping sickness. Preliminary results Annales de la Soci\u00e9t\u00e9 Belge de M\u00e9decine Tropicale 1995 65 71"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0016|cit16","doi-asserted-by":"crossref","unstructured":"Butler GC Duggan AJ Hutchinson MP Melarsen in the treatment of Trypanosoma gambiense infection in man Transactions of the Royal Society of Tropical Medicine and Hygiene 1957 69 74","DOI":"10.1016\/0035-9203(57)90009-3"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0017|cit17","unstructured":"Ceccaldi J [New contribution on arsobal (R.P. 3854) therapy of trypanosomiasis; its effectiveness in former trypanosomiasis patients, with meningoencephalitis, resistant to trypanocides customarily used.] Bulletin de la Societe de Pathologie Exotique et de ses Filiales 1953 95 121"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0018|cit18","doi-asserted-by":"crossref","unstructured":"Chappuis F Udayraj N Stietenroth K Meussen A Bovier PA Eflornithine is safer than melarsoprol for the treatment of second-stage Trypanosoma brucei gambiense human African trypanosomiasis Clinical Infectious Diseases 2005 748 51","DOI":"10.1086\/432576"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0019|cit19","unstructured":"Eozenou P Jannin J Ngampo S Carme B Tell GP Schechter PJ [A trial treatment with eflornithine of trypanosomiasis caused by Trypanosoma brucei gambiense in the Peoples Republic of the Congo] Medecine Tropicale (Marseilles) 1989 149 54"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0020|cit20","unstructured":"Janssens PG De Muynck A Clinical trials with \"nifurtimox\" in African trypanosomiasis Annales de la Soci\u00e9t\u00e9 Belge de M\u00e9decine Tropicale 1977 475 80"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0021|cit21","doi-asserted-by":"crossref","unstructured":"Khonde N Pepin J Mpia B A seven days course of eflornithine for relapsing Trypanosoma brucei gambiense sleeping sickness Transactions of the Royal Society of Tropical Medicine and Hygiene 1997 212 3","DOI":"10.1016\/S0035-9203(97)90228-5"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0022|cit22","unstructured":"Moens F De Wilde M Ngato K [Clinical trial of nifurtimox in human African trypanosomiasis] Annales de la Soci\u00e9t\u00e9 Belge de M\u00e9decine Tropicale 1984 37 43"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0023|cit23","doi-asserted-by":"crossref","unstructured":"Mpia B Pepin J Combination of eflornithine and melarsoprol for melarsoprol-resistant Gambian trypanosomiasis Tropical Medicine and International Health 2002 775 9","DOI":"10.1046\/j.1365-3156.2002.00933.x"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0024|cit24","doi-asserted-by":"crossref","unstructured":"Ogada T Fink E Mbwabi D Clinical trials of diamidine 98-202 in Rhodesian sleeping sickness Transactions of the Royal Society of Tropical Medicine and Hygiene 1973 280 1","DOI":"10.1016\/0035-9203(73)90197-1"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0025|cit25","unstructured":"Pepin J Tetreault L Gervais C [The use of oral corticosteroids in the treatment of human African trypanosomiasis: a retrospective survey in Nioki, Zaire] Annales de la Soci\u00e9t\u00e9 Belge de M\u00e9decine Tropicale 1985 17 29"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0026|cit26","doi-asserted-by":"crossref","unstructured":"Pepin J Milord F Mpia B Meurice F Ethier L DeGroof D An open clinical trial of nifurtimox for arseno-resistant Trypanosoma brucei gambiense sleeping sickness in central Zaire Transactions of the Royal Society of Tropical Medicine and Hygiene 1989 514 7","DOI":"10.1016\/0035-9203(89)90270-8"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0027|cit27","doi-asserted-by":"crossref","unstructured":"Schmid C Richer M Bilenge CM Josenando T Chappuis F Manthelot CR Effectiveness of a 10-day melarsoprol schedule for the treatment of late-stage human African trypanosomiasis: confirmation from a multinational study (IMPAMEL II) Journal of Infectious Diseases 2005 1922 31","DOI":"10.1086\/429929"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0028|cit28","doi-asserted-by":"crossref","unstructured":"Van Nieuwenhove S Schechter PJ Declercq J Bone G Burke J Sjoerdsma A Treatment of gambiense sleeping sickness in the Sudan with oral DFMO (DL-alpha-difluoromethylornithine), an inhibitor of ornithine decarboxylase; first field trial Transactions of the Royal Society of Tropical Medicine and Hygiene 1985 692 8","DOI":"10.1016\/0035-9203(85)90195-6"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0029|cit29","unstructured":"Pivotal Study of Fexinidazole for Human African Trypanosomiasis in Stage 2 Ongoing study September 2012"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0030|cit30","unstructured":"Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158 Ongoing study February 2012"},{"issue":"2","key":"10.1002\/14651858.CD006201.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/cid\/cis886","article-title":"Nifurtimox-eflornithine combination therapy for second-stage gambiense human African trypanosomiasis: medecins sans frontieres experience in the democratic republic of the congo","volume":"56","author":"Alirol","year":"2013","journal-title":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"},{"issue":"3","key":"10.1002\/14651858.CD006201.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.trstmh.2008.09.005","article-title":"Effectiveness of melarsoprol and eflornithine as first-line regimens for gambiense sleeping sickness in nine Medecins Sans Frontieres programmes","volume":"103","author":"Balasegaram","year":"2009","journal-title":"Transactions of the Royal Society of Tropical Medicine and Hygiene"},{"issue":"2","key":"10.1002\/14651858.CD006201.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1046\/j.1472-8206.2003.00167.x","article-title":"Treatment perspectives for human African trypanosomiasis","volume":"17","author":"Bouteille","year":"2003","journal-title":"Fundamental and Clinical Pharmacology"},{"issue":"9709","key":"10.1002\/14651858.CD006201.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(09)60829-1","article-title":"Human African trypanosomiasis","volume":"375","author":"Brun","year":"2010","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00436-002-0766-5","article-title":"Eflornithine for the treatment of human African trypanosomiasis","volume":"90 Suppl 1","author":"Burri","year":"2003","journal-title":"Parasitology Research"},{"issue":"5","key":"10.1002\/14651858.CD006201.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1046\/j.1365-3156.2001.00669.x","article-title":"Sleeping sickness surveillance: an essential step toward elimination","volume":"6","author":"Cattand","year":"2001","journal-title":"Tropical Medicine and International Health"},{"issue":"11","key":"10.1002\/14651858.CD006201.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1086\/522983","article-title":"Melarsoprol-free drug combinations for second-stage Gambian sleeping sickness: the way to go","volume":"45","author":"Chappuis","year":"2007","journal-title":"Clinical Infectious Diseases"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0038|cit38","unstructured":"DNDi Nifurtimox-Eflornithine Combination Therapy: An Improved Treatment for Sleeping Sickness DNDi Newsletter November 2008"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0039|cit39","unstructured":"IMPAMEL III http:\/\/www.swisstph.ch\/services\/medicines-research\/pharmaceutical-medicine\/experience\/impamel-iii.html"},{"issue":"7303","key":"10.1002\/14651858.CD006201.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1136\/bmj.323.7303.42","article-title":"Systematic reviews in health care: Assessing the quality of controlled clinical trials","volume":"323","author":"J\u00fcni","year":"2001","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0041|cit41","article-title":"Chapter 6: Searching for studies","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Lefebvre","year":"2011"},{"issue":"7","key":"10.1002\/14651858.CD006201.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1473-3099(02)00321-3","article-title":"Treatment of human African trypanosomiasis-present situation and needs for research and development","volume":"2","author":"Legros","year":"2002","journal-title":"Lancet Infectious Diseases"},{"issue":"5","key":"10.1002\/14651858.CD006201.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-3156.2005.01403.x","article-title":"Review Article: cerebrospinal fluid in human African trypanosomiasis: a key to diagnosis, therapeutic decision and post-treatment follow-up","volume":"10","author":"Lejon","year":"2005","journal-title":"Tropical Medicine and International Health"},{"issue":"1","key":"10.1002\/14651858.CD006201.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00436-002-0799-9","article-title":"Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis","volume":"90","author":"Nok","year":"2003","journal-title":"Parasitology Research"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0065-308X(08)60410-8","article-title":"The treatment of human African trypanosomiasis","volume":"33","author":"Pepin","year":"1994","journal-title":"Advances in Parasitology"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0065-308X(01)49038-5","article-title":"The epidemiology and control of human African trypanosomiasis","volume":"49","author":"Pepin","year":"2001","journal-title":"Advances in Parasitology"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0047|cit47","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2008"},{"issue":"11","key":"10.1002\/14651858.CD006201.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"e1920","DOI":"10.1371\/journal.pntd.0001920","article-title":"In-Hospital Safety in Field Conditions of Nifurtimox Eflornithine Combination Therapy (NECT) for T. b. gambiense Sleeping Sickness","volume":"6","author":"Schmid","year":"2012","journal-title":"PLoS neglected tropical diseases"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0049|cit49","first-page":"65","article-title":"Chemotherapy of African trypanosomiasis","volume-title":"The African trypanosomes. Series: World Class Parasites, Vol. 1","author":"Seed","year":"2001"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0050|cit50","volume-title":"Investigations on the encephalopathic syndrome during melarsoprol treatment of Human African Trypanosomiasis [PhD thesis]","author":"Seixas","year":"2005"},{"issue":"2","key":"10.1002\/14651858.CD006201.pub3-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"e55","DOI":"10.1371\/journal.pmed.0050055","article-title":"Eliminating human African trypanosomiasis: where do we stand and what comes next?","volume":"5","author":"Simarro","year":"2008","journal-title":"PLoS Medicine"},{"issue":"7357","key":"10.1002\/14651858.CD006201.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1136\/bmj.325.7357.203","article-title":"Human African trypanosomiasis","volume":"325","author":"Stich","year":"2002","journal-title":"BMJ"},{"issue":"5","key":"10.1002\/14651858.CD006201.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S1471-4922(03)00055-2","article-title":"Waking up to sleeping sickness","volume":"19","author":"Stich","year":"2003","journal-title":"Trends in Parasitology"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0054|cit54","first-page":"39","article-title":"Advances in sleeping sickness therapy","volume":"72 Suppl 1","author":"Nieuwenhove","year":"1992","journal-title":"Annales de la Soci\u00e9t\u00e9 Belge de M\u00e9decine Tropicale"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0055|cit55","unstructured":"Control and surveillance of African trypanosomiasis. Report of a WHO Expert Committee World Health Organization Technical Report Series 1998 1 114"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0056|cit56","unstructured":"World Health Organization Recommendations of the Informal consultation on Issue for Clinical Product development for human African Trypanosomiasis http:\/\/www.who.int\/neglected_diseases\/mediacentre\/Final%20Clinical_products_for_trypanosomiasis%20November%2007.pdf 2004"},{"issue":"8","key":"10.1002\/14651858.CD006201.pub3-BIB0057|cit57","first-page":"71","article-title":"Human African trypanosomiasis (sleeping sickness): epidemiological update","volume":"81","author":"WHO","year":"2006","journal-title":"Releve epidemiologique hebdomadaire \/ Section d'hygiene du Secretariat de la Societe des Nations = Weekly epidemiological record \/ Health Section of the Secretariat of the League of Nations"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0058|cit58","unstructured":"WHO Secretariat Progress Report (http:\/\/who.int\/gb\/ebwha\/pdf_files\/EB126\/B126_38-en.pdf)"},{"key":"10.1002\/14651858.CD006201.pub3-BIB0059|cit59","unstructured":"WHO WHO model list of essential medicines, 16th list (updated) March 2010"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD006201.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T17:09:31Z","timestamp":1725469771000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006201.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Infectious Diseases Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2013,6,28]]},"references-count":59,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2013,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006201.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6,28]]}}}